Payer Almanac
About the data Sign in
Star measuresDisplay measuresHEDISWhy members leave

Measures · D09 in 2027 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing

Medication Adherence for Hypertension (RAS antagonists)

Drug PlanMedication AdherenceSource: Prescription Drug Events

What it measures
The percentage of plan members with a prescription for a blood pressure medication who fill their prescription often enough to cover 80% or more of the time they are taking the medication. One of the most important ways people with high blood pressure can manage their health is by taking their medication. The plan, the doctor, and the member can work together to do this. (“Blood pressure medication” means an ACE (angiotensin converting enzyme) inhibitor, an ARB (angiotensin receptor blocker), or a direct renin inhibitor drug.)
How it's calculated
This measure is defined as the percentage of Medicare Part D beneficiaries, 18 years and older, who adhere to their prescribed drug therapy for renin angiotensin system (RAS) antagonists: ACE inhibitor, ARB, or direct renin inhibitor medications. The proportion of days covered (PDC) is the percentage of days in the treatment period “covered” by prescription claims for the same medication or another in its therapeutic category. The index prescription start date (IPSD) is the earliest date of service for the target medication during the measurement year. The treatment period begins on the IPSD and extends through whichever comes first: the last day of enrollment during the measurement year, death, or the end of the measurement year. The treatment period must be at least 91 days during the measurement year. Continuous enrollment (CE) is defined as being continuously enrolled in a Medicare Part D contract during the treatment period with no enrollment gaps allowed during the treatment period. This percentage is calculated as the number of continuously enrolled beneficiaries, 18 years and older, with a PDC of 80 percent or higher for RAS antagonist medications during the treatment period (numerator) divided by the number of continuously enrolled beneficiaries, 18 years and older, with at least two RAS antagonist medication fills on unique dates of service during the treatment period, and a treatment period that is at least 91 days during the measurement year (denominator). The Part D Medication Adherence measure is adapted from the Medication Adherence- Proportion of Days Covered measure that was developed and endorsed by the PQA. See the medication list for this measure. The Part D Medication Adherence rate is calculated using the NDC list maintained by the PQA. The complete NDC list, including diagnosis codes, is posted along with these technical notes.
Data source
Prescription Drug Event (PDE) data The data for this measure come from PDE data submitted to the CMS DDPS and accepted by the 2025 PDE submission deadline for annual Part D payment reconciliation with dates of service from January 1, 2025-December 31, 2025. If the PDE edit results in the PDE being rejected by DDPS, then the PDE is not used in the Patient Safety measure calculations. If the PDE edit is informational and therefore does not result in the PDE being rejected, then the PDE is used in the Patient Safety measure calculations. Reminder, CMS uses the term “final action” PDE to describe the most recently accepted original, adjustment, or deleted PDE record representing a single dispensing event. Original and adjustment final action PDEs submitted by the sponsor and accepted by DDPS prior to the 2025 PDE submission deadline are used to calculate this measure. PDE claims are limited to members who received at least two prescriptions on unique dates of service for RAS antagonist medication(s). PDE adjustments made post-reconciliation were not reflected in this measure. Additional data sources include the CME, the CWF, and the EDS. The data cutoff date for all the additional data sources listed below such as the CME, CWF, and EDS is determined by the same PDE submission deadline for the annual Part D payment reconciliation. • CME is used for enrollment information and to identify beneficiaries who elected to receive hospice care or with ESRD status (dialysis start and end dates within the measurement period). • CWF is used to identify exclusion diagnoses based on ICD-10-CM codes (on inpatient, outpatient, or carrier claims), inpatient and SNF stays for PDPs and MA-PDs (if available). • EDS is used to identify exclusion diagnoses based on ICD-10-CM codes (on inpatient, outpatient, or carrier claims), and SNF/IP stays for MA-PD beneficiaries.
Measurement period
01/01/2025 – 12/31/2025
Better when
Higher
Weight
3 (Intermediate Outcome Measure)
Star assignment
Clustering
Case-mix adjusted
No
In improvement measure
Yes
Used in CAI
Yes
Exclusions
ShowContracts with 29 or fewer continuously enrolled beneficiaries (in the denominator). The following beneficiaries are also excluded from the denominator if at any time during the measurement period unless otherwise specified: • In hospice • ESRD diagnosis or dialysis coverage dates • One or more prescriptions for sacubitril/valsartan during the treatment period
Notes
Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the PQA medication or NDC lists, are excluded from CMS analyses. The PDC calculation is adjusted for overlapping prescriptions for the same drug which is defined by active ingredient at the generic name level using the NDC list maintained by PQA. The calculation also adjusts for Part D beneficiaries’ stays in IP settings and stays in SNFs. The discharge date is included as an adjustment day for IP/SNF stays. Please see Attachment L: Medication Adherence Measure Calculations for more information about these calculation adjustments. When available, beneficiary death date from the CME is the end date of a beneficiary’s treatment period.
Disaster policy
Higher measure star (2026-2027) for contracts with 25% or more enrolled affected by 2025 disasters.

From the 2027 Star Ratings Technical Notes (CMS).

Cut points over time

Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.

How the 2028 cut points are projected

Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.

StarsOrg type2027Projected 2028Move
2★MA-PD8485+1
3★MA-PD8889+1
4★MA-PD9091+1
5★MA-PD9394+1
2★PDP8788+1
3★PDP8990+1
4★PDP9091+1
5★PDP92920

2027 star distribution

Not rated: Plan too new to be measured (94); Not enough data available (23); Plan not required to report measure (8)

Cut point bands

Star yearOrg type1★2★3★4★5★
2027MA-PD< 84 %>= 84 % to < 88 %>= 88 % to < 90 %>= 90 % to < 93 %>= 93 %
2027PDP< 87 %>= 87 % to < 89 %>= 89 % to < 90 %>= 90 % to < 92 %>= 92 %
2026MA-PD< 84 %>= 84 % to < 88 %>= 88 % to < 91 %>= 91 % to < 93 %>= 93 %
2026PDP< 88 %>= 88 % to < 90 %>= 90 % to < 91 %>= 91 % to < 93 %>= 93 %
2025MA-PD< 83 %>= 83 % to < 87 %>= 87 % to < 90 %>= 90 % to < 92 %>= 92 %
2025PDP< 87 %>= 87 % to < 89 %>= 89 % to < 90 %>= 90 % to < 92 %>= 92 %
2024MA-PD< 82 %>= 82 % to < 86 %>= 86 % to < 89 %>= 89 % to < 91 %>= 91 %
2024PDP< 87 %>= 87 % to < 89 %>= 89 % to < 91 %>= 91 % to < 94 %>= 94 %
2023MA-PD< 78 %>= 78 % to < 86 %>= 86 % to < 89 %>= 89 % to < 91 %>= 91 %
2023PDP< 86 %>= 86 % to < 89 %>= 89 % to < 91 %>= 91 % to < 96 %>= 96 %
2022MA-PD< 74 %>= 74 % to < 82 %>= 82 % to < 87 %>= 87 % to < 90 %>= 90 %
2022PDP< 85 %>= 85 % to < 88 %>= 88 % to < 89 %>= 89 % to < 91 %>= 91 %
2021MA-PD< 80 %>= 80 % to < 84 %>= 84 % to < 87 %>= 87 % to < 89 %>= 89 %
2021PDP< 84 %>= 84 % to < 86 %>= 86 % to < 88 %>= 88 % to < 90 %>= 90 %
2020MA-PD< 80%? 80% to < 83%? 83% to < 86%? 86% to < 88%? 88%
2020PDP< 83%? 83% to < 85%? 85% to < 88%? 88% to < 90%? 90%
2019MA-PD< 79%? 79% to < 83%? 83% to < 86%? 86% to < 88%? 88%
2019PDP< 84%? 84% to < 86%? 86% to < 87%? 87% to < 89%? 89%
2018MA-PD< 74%? 74% to < 78%? 78% to < 82%? 82% to < 85%? 85%
2018PDP< 78%? 78% to < 83%? 83% to < 86%? 86% to < 89%? 89%
2017MA-PD< 71%? 71% to < 75%? 75% to < 79%? 79% to < 83%? 83%
2017PDP< 77%? 77% to < 80%? 80% to < 83%? 83% to < 85%? 85%
2016MA-PD< 58%? 58% to < 73%? 73% to < 77%? 77% to < 81%? 81%
2016PDP< 76%? 76% to < 78%? 78% to < 82%? 82% to < 85%? 85%
2015MA-PD< 72%? 72% to < 76%? 76% to < 81%? 81% to < 85%? 85%
2015PDP< 72%? 72% to < 76%? 76% to < 81%? 81% to < 84%? 84%

Lowest-scoring contracts, 2027

ContractParentMembersScoreStarsΔShortfall to 4★Pctile
S4983 Kaiser PermanenteKaiser Foundation Health Plan, Inc.6,628861—40%
S0375 CareFirst BlueCross BlueShield Group Prescription Drug PlanCareFirst, Inc.549861—40%
H3467 ProCare AdvantageFirst Sacramento Capital Funding LLC1,0106610240%
H4232 American Health Advantage of UtahMitchell Family Office296741−1160%
H9066 Nascentia Health PlusVISITING NURSE ASSOCIATION OF CENTRAL NEW YORK6637610140%
H3800 Provider Partners Health PlansRifkin Managed Care Holding, LLC1,0797710131%
H4054 Provider Partners Health PlansRifkin Managed Care Holding, LLC2,4857910111%
H4490 American Health Advantage of MissouriMitchell Family Office832801−1101%
H8176 Molina Healthcare of South CarolinaMolina Healthcare, Inc.3,128801−1101%
H9917 Align Senior CareCurana Health Holdings, LLC408811091%
H8332 Aetna MedicareCVS Health Corporation197811−291%
H8879 Healthy Mississippi, Inc.Singh Holdings LLC500811—91%
H4739 First Choice VIP Care (HMO D-SNP)Independence Health Group, Inc.2,519821−182%
H0738 AmeriHealth Caritas VIP Care (HMO-D-SNP)Independence Health Group, Inc.1,048821−182%
H3407 El Paso Health Medicare AdvantageEl Paso County Hospital District2,178821082%
H3810 AllCare AdvantageAllCare Health, Inc.2,485831−172%
H4869 Gold Kidney Health PlanGold Kidney Health Plan6,263831−172%
H9431 Aetna MedicareCVS Health Corporation666831−272%
H5580 Mercy Care AdvantageMercy Care10,965842+163%
H8854 CareFirst BlueCross BlueShield Advantage DualPrimeCareFirst, Inc.8,599842+163%
H2400 Abilis Health (HMO SNP)BrightSpring Health Services, Inc.1,139842063%
H2247 UnitedHealthcareUnitedHealth Group, Inc.39,518842063%
H2034 Community CareCareSource310842063%
H5163 Verda Health Plan of TexasVerda Healthcare, Inc.3,889842−163%
H2237 iCareHumana Inc.938852054%

History

Star yearCodeNameMeasuredWeightSource
2027D09Medication Adherence for Hypertension (RAS antagonists)01/01/2025 – 12/31/20253Prescription Drug Events
2026D09Medication Adherence for Hypertension (RAS antagonists)01/01/2024 – 12/31/20243Prescription Drug Events
2025D09Medication Adherence for Hypertension (RAS antagonists)01/01/2023 – 12/31/20233Prescription Drug Events
2024D09Medication Adherence for Hypertension (RAS antagonists)01/01/2022 – 12/31/20223Prescription Drug Events
2023D09Medication Adherence for Hypertension (RAS antagonists)01/01/2021 – 12/31/20213Prescription Drug Events
2022D09Medication Adherence for Hypertension (RAS antagonists)01/01/2020 – 12/31/20203Prescription Drug Events
2021D11Medication Adherence for Hypertension (RAS antagonists)01/01/2019 – 12/31/20193Prescription Drug Events
2020D11Medication Adherence for Hypertension (RAS antagonists)01/01/2018 – 12/31/20183Prescription Drug Events
2019D11Medication Adherence for Hypertension (RAS antagonists)01/01/2017 – 12/31/20173Prescription Drug Events
2018D12Medication Adherence for Hypertension (RAS antagonists)01/01/2016 – 12/31/20163Prescription Drug Events
2017D13Medication Adherence for Hypertension (RAS antagonists)01/01/2015 - 12/31/20153Prescription Drug Events
2016D13Medication Adherence for Hypertension (RAS antagonists)01/01/2014 - 12/31/20143Prescription Drug Events
2015D12Medication Adherence for Hypertension (RAS antagonists)01/01/2013 - 12/31/20133Prescription Drug Events